CBD and bipolar disorders - what you should know (FAQ)

Bipolar affective disorder (BAD) is a serious psychiatric illness characterized by alternating episodes of mania and depression. Treatment is long-term and includes mood stabilizers and often antipsychotic or antidepressant medications. More and more people with BAD are asking about CBD - whether it can help with the anxiety associated with the illness, with sleep, or with depressive symptoms between episodes. The question is justified, but the answer is ambiguous and fraught with serious reservations regarding drug interactions. Patel and colleagues in their 2023 review in Journal of Affective Disorders emphasize that there is very little clinical data on CBD in BPAD and clinical recommendations cannot yet be formulated (Patel et al., Journal of Affective Disorders, 2023). This article gathers what is known - and equally importantly: what is still unknown.

KEY INFORMATION
• CBD is not a mood stabilizer and does not replace mood stabilizers used in BAD - there are no clinical studies confirming this (Patel et al., Journal of Affective Disorders, 2023).
• CBD may interact with psychiatric medications by inhibiting CYP3A4 and CYP2D6 - consultation with a psychiatrist is absolutely necessary before starting CBD.
• THC is contraindicated in BAD - it increases the risk of manic and psychotic episodes.
• WHO (2018) confirms the good safety profile of CBD itself, but not in the context of polytherapy in psychiatry.

What do studies say about CBD in bipolar disorders?

There are very few clinical studies on CBD in BAD - and this is the first important piece of information. Most available data comes from preclinical studies (on cells and animal models) or from small observational studies on general populations with affective disorders. CBD exhibits anxiolytic properties by activating the serotonin receptor 5-HT1A and modulating PPAR-γ pathways. Neuroprotective and anti-inflammatory properties of CBD have also been observed in animal models, which is interesting because low-grade inflammation is being studied as one of the pathophysiological factors in BAD.

However, there is a gap between interesting preclinical results and proven clinical efficacy in BAD. The review by Patel et al. from 2023 analyzed the available data and concluded that there is insufficient evidence to recommend CBD as a therapy for BAD. At the same time, the authors note that there is also no evidence that CBD worsens the course of the disease - hence the scope for further clinical research remains open. For patients with BAD, this translates to one thing: based on current data, it cannot be claimed that CBD 'cures' or 'stabilizes' the course of BAD.

CBD interactions with psychiatric medications - the most important issue

This is an absolutely crucial topic for anyone with BPAD considering CBD. Cannabidiol inhibits the activity of cytochrome P450 enzymes, primarily CYP3A4 and CYP2D6 (Bruni et al., Molecules, 2018). These are the same enzymes that metabolize a significant portion of psychiatric medications used in BPAD:

Quetiapine (Seroquel), olanzapine (Zyprexa), and other atypical antipsychotics are primarily metabolized by CYP3A4. Inhibition of this enzyme by CBD may raise the levels of these medications in the blood, increasing the risk of side effects - sedation, heart rhythm disturbances, metabolic syndrome. Lamotrigine (Lamictal), used as a mood stabilizer, is metabolized via a different pathway (UGT), but concurrent use with CBD requires monitoring. Benzodiazepines (clonazepam, lorazepam) used as needed in BAD are metabolized by CYP3A4 - the risk of increased sedation when combined with CBD is real.

Practical conclusion: if you are taking medications from the above group and want to incorporate CBD, your treating psychiatrist must be informed and should consider monitoring drug levels. Self-initiating CBD in psychiatric polytherapy can destabilize treatment without an obvious reason.

THC a choroba dwubiegunowa - dlaczego jest przeciwwskazany?

Unlike CBD, THC is contraindicated in BAD - and this is definite. A meta-analysis by Gibbs and colleagues published in Bipolar Disorders in 2015 analyzed cohort study results and showed that cannabis use (containing THC) by individuals with bipolar disorder is associated with an earlier onset of the disease, a higher number of psychiatric hospitalizations, poorer response to mood stabilizers, and more frequent manic episodes with psychotic symptoms (Gibbs et al., Bipolar Disorders, 2015). THC is a full agonist of the CB1 receptor in the brain and can directly destabilize dopaminergic and serotonergic systems involved in the pathophysiology of bipolar disorder.

This practically means: individuals with BAD should avoid full-spectrum CBD products containing THC and choose only broad-spectrum products or CBD isolate with a CoA certificate confirming zero or trace (<0.05%) THC content. This is not a matter of excessive caution - it is a real safety concern.

CBD and sleep in bipolar disorders

Sleep deprivation is one of the strongest known triggers for manic episodes in BAD. Regular, good-quality sleep is one of the pillars of mood stabilization alongside pharmacotherapy and psychotherapy. CBD in studies shows supportive effects on sleep through several mechanisms: it shortens the time to fall asleep, may prolong deep sleep (NREM) phase, and reduces anxiety associated with falling asleep - effects that indirectly promote sleep quality (Shannon et al., The Permanente Journal, 2019).

For individuals with BAD, for whom sleep is a particularly sensitive clinical parameter, this property of CBD is potentially interesting. It is not about treating mania or depression with CBD - it is about supporting one of the hygiene factors that affects the course of the disease. However, even in this limited context, consultation with a psychiatrist is necessary: many medications used in BAD (sedatives, atypical antipsychotics) themselves affect sleep and sleep architecture, and CBD through interactions with CYP3A4 may alter their concentrations. Adding CBD to polytherapy without the psychiatrist's knowledge may disrupt the therapeutic effects of medications that the patient is already taking for sleep and mood stabilization.

Frequently Asked Questions

Can CBD help with bipolar disorder?

Clinical studies on CBD in bipolar disorder are very limited and do not allow for clinical recommendations. CBD exhibits anxiolytic and neuroprotective properties in preclinical studies, but it is not a mood stabilizer and does not replace mood stabilizers. CBD may be considered as an adjunct to therapy only under the supervision of a psychiatrist (Patel et al., Journal of Affective Disorders, 2023).

Can CBD interact with medications for bipolar disorder?

Yes - this is a key issue. CBD inhibits the enzymes CYP3A4 and CYP2D6, which metabolize many psychiatric medications, including quetiapine, olanzapine, and benzodiazepines. Inhibition of these enzymes can raise drug levels to potentially toxic levels. Consultation with a psychiatrist before starting CBD is absolutely necessary (Bruni et al., Molecules, 2018).

Is THC safe in bipolar disorder?

No. The meta-analysis by Gibbs et al. showed that cannabis use (containing THC) is associated with an earlier onset of bipolar disorder, more frequent manic episodes, and poorer treatment response. Individuals with bipolar disorder should avoid all products containing THC and use only CBD with a certificate of zero THC content (Gibbs et al., Bipolar Disorders, 2015).

What properties of CBD may be beneficial in bipolar disorder?

The anxiolytic properties of CBD (reducing anxiety associated with BAD through the 5-HT1A receptor) and sleep-supporting effects (sleep deprivation triggers episodes) may be potentially useful. However, this is not a treatment for BAD - these are nonspecific effects that could support overall health, not stabilize mood.

Can CBD cause mania or depression?

There is no evidence that CBD alone triggers manic or depressive episodes. CBD does not strongly activate CB1 receptors and does not exhibit psychomimetic properties unlike THC. Cases of mood deterioration reported with 'CBD' often involve products containing undeclared THC or other active ingredients.

How to talk to a psychiatrist about CBD in bipolar disorder?

Tell your psychiatrist specifically: what form of CBD you are considering (oil, capsule), what concentration in mg, how often, and for what purpose. The psychiatrist needs to assess potential interactions with your medications - especially mood stabilizers and antipsychotics. Do not start using CBD before this conversation. Changes in medication levels in the blood due to enzymatic interactions can destabilize your mood without an obvious cause.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04